KR20030016774A - Compositions Comprising Antofine And The Use Thereof - Google Patents
Compositions Comprising Antofine And The Use Thereof Download PDFInfo
- Publication number
- KR20030016774A KR20030016774A KR1020010050497A KR20010050497A KR20030016774A KR 20030016774 A KR20030016774 A KR 20030016774A KR 1020010050497 A KR1020010050497 A KR 1020010050497A KR 20010050497 A KR20010050497 A KR 20010050497A KR 20030016774 A KR20030016774 A KR 20030016774A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- cancer cells
- column chromatography
- silica gel
- cells
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- NCVWJDISIZHFQS-CQSZACIVSA-N (-)-antofine Chemical compound C12=CC(OC)=C(OC)C=C2C2=CC(OC)=CC=C2C2=C1C[C@H]1CCCN1C2 NCVWJDISIZHFQS-CQSZACIVSA-N 0.000 title abstract description 18
- NCVWJDISIZHFQS-UHFFFAOYSA-N tylophorine B Natural products C12=CC(OC)=C(OC)C=C2C2=CC(OC)=CC=C2C2=C1CC1CCCN1C2 NCVWJDISIZHFQS-UHFFFAOYSA-N 0.000 title abstract description 9
- 229930008659 antofine Natural products 0.000 title abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 54
- 201000011510 cancer Diseases 0.000 claims abstract description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 230000010261 cell growth Effects 0.000 claims abstract description 14
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 230000001093 anti-cancer Effects 0.000 claims abstract description 8
- 230000003013 cytotoxicity Effects 0.000 claims abstract description 8
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 241001474374 Blennius Species 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 240000007124 Brassica oleracea Species 0.000 claims 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims 1
- 244000241235 Citrullus lanatus Species 0.000 claims 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims 1
- 241000331449 Vincetoxicum pycnostelma Species 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 239000003966 growth inhibitor Substances 0.000 abstract description 2
- 238000004809 thin layer chromatography Methods 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 239000003480 eluent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 64
- 206010009944 Colon cancer Diseases 0.000 description 19
- 208000029742 colonic neoplasm Diseases 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 13
- 201000005202 lung cancer Diseases 0.000 description 13
- 208000020816 lung neoplasm Diseases 0.000 description 13
- 239000000126 substance Substances 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229930013930 alkaloid Natural products 0.000 description 6
- 150000003797 alkaloid derivatives Chemical class 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 4
- 235000017491 Bambusa tulda Nutrition 0.000 description 4
- 241001330002 Bambuseae Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000011425 bamboo Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000009852 Cucurbita pepo Nutrition 0.000 description 3
- 241000219104 Cucurbitaceae Species 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- RJYQLMILDVERHH-UHFFFAOYSA-N 4-Ipomeanol Chemical compound CC(O)CCC(=O)C=1C=COC=1 RJYQLMILDVERHH-UHFFFAOYSA-N 0.000 description 2
- 241000208327 Apocynaceae Species 0.000 description 2
- 101100328886 Caenorhabditis elegans col-2 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000427940 Fusarium solani Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 150000005692 lignans Chemical class 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241001290610 Abildgaardia Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000759909 Camptotheca Species 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 240000002559 Cephalotaxus drupacea Species 0.000 description 1
- 235000012649 Cephalotaxus drupacea Nutrition 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000587240 Cynanchum Species 0.000 description 1
- 241001664021 Cynanchum ascyrifolium Species 0.000 description 1
- 241000287222 Drupa Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 244000236480 Podophyllum peltatum Species 0.000 description 1
- 235000008562 Podophyllum peltatum Nutrition 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- 241000202349 Taxus brevifolia Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000028204 Vincetoxicum atratum Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003394 isomerase inhibitor Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940060975 lantus Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000010731 swelling symptom Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Abstract
Description
본 발명은 새로운 항암제에 관한 것이다. 보다 상세히는 천연물 생약 산해박 추출물에서 유래된 것으로, 사람 폐암세포 및 사람 결장암세포에 독성을 나타내고 이들 암세포의 성장을 저해하는 하기 화학식 (I)로 표현되는 화합물 안토파인(antofine) 및 그 유도체에 관한 것이다.The present invention relates to a new anticancer agent. More specifically, it is derived from the natural herbal herbal extracts, and relates to the compound antofine and its derivatives represented by the following general formula (I) which is toxic to human lung cancer cells and human colon cancer cells and inhibits the growth of these cancer cells will be.
우리나라 통계청에서 최근 발표한 자료에 의하면 암으로 인한 사망률이 1990년 인구 십만명 당 110.4명에서 1999년에는 114.7명으로 약 10년간 무려 3.9%가 증가한 것으로 나타났다. 1999년 현재 지난 1990년에 비해 사망률이 증가한 경우로는 폐암 (1990년 14.4명→1999년 22.1명), 대장암(1990년 4.5명→1999년 7.9명), 췌장암(1990년 3.3명→1999년 5.4명), 여성유방암(1990년 3.5명→1999년 4.8명) 및 전립선암(1990년 1.6명→1999년 1.8명)이 있다. 폐암은 인구의 노령화, 흡연인구의 증가 및 대기오염의 심화로 크게 증가하고 있으며, 대장암, 췌장암, 유방암, 전립선암 등도 식생활의 서구화에 따른 고지방식의 섭취, 환경오염 물질의 증가, 음주 섭취량의 증가 등으로 지속적으로 증가하는 추세이다.According to recent data released by the Korea National Statistical Office, the mortality rate from cancer increased by 3.9% over the past 10 years, from 110.4 per 100,000 population in 1990 to 114.7 in 1999. As of 1999, mortality rates increased from 14.4 in 1990 to 22.1 in 1999, colorectal cancer (4.5 in 1990 → 7.9 in 1999), and pancreatic cancer (3.3 in 1990 → 1999). 5.4), female breast cancer (3.5 in 1990 → 4.8 in 1999) and prostate cancer (1.6 in 1990 → 1.8 in 1999). Lung cancer has increased significantly due to the aging of the population, the increase in the smoking population, and the deepening of air pollution.In addition, colon cancer, pancreatic cancer, breast cancer, and prostate cancer are also affected by high-fat diets, environmental pollutants, and alcohol consumption. It is steadily increasing due to the increase.
암세포는 정상세포와 많은 면에서 그 성질이 유사하므로 정상세포에는 피해를 주지 않고 암세포만을 제거하는 것은 쉬운일이 아니다. 그러나 암세포에는 몇가지 일반 세포와 구분되는 특징이 있는 데, 첫째는 암세포는 세포 증식이 조절되지 않는다는 것이고, 둘째는 분화의 특징이 비교적 결여되어 있다는 것이며, 셋째는 주위의 조직에 침투하여 전이를 한다는 것이다. 정상세포는 필요에 따라 성장인자에 의해 신호를 전달받아 증식을 하는 반면 암세포는 성장인자에 대한 의존도가 낮고 주변의 세포와 접촉에 의해 성장이 저해되는 접촉성 저해 (contact inhibition)가 없으며, 안지오제닉 인자 (angiogenic factor)를 분비하여 전이를 활발히 한다. 또한 암세포는 분화가 되지 않고, 세포사멸 (apoptosis or programmed cell death)이 일어나지 않으며, 유전적으로 불안정한 특징이 있다. 암세포의 유전적인 불안정은 암의 진행에 있어서 매우 중요하며 화학요법제에 대한 내성을 유도하기도 하는 것으로 알려져 있다 (Folksman et al., Science,235,442-447 (1987); Liotta et al., Cell,64,327-336 (1991)).Because cancer cells have many similar properties to normal cells, it is not easy to remove cancer cells without damaging normal cells. However, cancer cells are distinguished from several normal cells, firstly, cancer cells are not regulated in cell proliferation, secondly, they are relatively lacking in differentiation characteristics, and thirdly, they invade and metastasize to surrounding tissues. . Normal cells proliferate by receiving signals from growth factors as needed, while cancer cells have low dependence on growth factors and do not have contact inhibition, which inhibits growth by contact with surrounding cells. Secrete angiogenic factor to promote metastasis. In addition, cancer cells are not differentiated, do not cause apoptosis or programmed cell death, and have genetically unstable characteristics. Genetic instability of cancer cells is very important in cancer progression and is known to induce resistance to chemotherapeutic agents (Folksman et al., Science, 235, 442-447 (1987); Liotta et al., Cell , 64, 327-336 (1991)).
암의 치료 방법으로는 수술요법, 화학요법, 방사선 치료법 등이 널리 쓰인다. 이 중 화학요법이 가장 많이 연구되어 있는데, 현재 사용되고 있는 화학요법제로는 알킬화제 (alkylating agent), 대사저해제 (metabolic inhibitor), DNA 결합제 (DNA-binders), 튜불린 (tubulin)에 작용하는 약물, 토포아이소머라제 (topoisomerase) 저해제, 기타 DNA에 작용하는 약물들이 있으나 이들이 다양한 종류의 암, 특히 증식 속도가 느린 고형암을 치료하는데 한계를 드러내고 있기 때문에 새로운 항암제의 개발이 아직도 절실히 요구되고 있다.As a cancer treatment method, surgery, chemotherapy and radiation therapy are widely used. Among them, chemotherapy is the most studied. Currently used chemotherapeutic agents include alkylating agents, metabolic inhibitors, DNA-binders, drugs that act on tubulin, and topo. Although there are isomerase inhibitors and other drugs that act on DNA, the development of new anticancer drugs is still urgently needed because they are limited in treating various types of cancers, especially solid cancers with slow growth.
지구상에는 약 150,000종의 식물이 존재한다. 식물은 항암제의 개발에 중요한 자원이 되고 있으며 그 예로는 칸타란투스 로세우스(Catharanthus roseus)에서 분리된 알칼로이드 (alkaloid)인 빈브라스틴(vinblastine), 포도필룸 펠타툼 (Podophyllum peltatum)에서 분리된 리그난 (lignan)인 포도필로톡신 (podophyllotoxin)의 반합성 유도체인 에토포사이드 (etoposide)와 테니포사이드 (teniposide), 택서스 브레비폴리아(Taxus brevifolia)에서 분리된 택솔 (taxol), 캄토테카 아쿠미나타(Camptotheca accuminata)에서 분리된 캄토테신 (camptothecine), 세팔로택서스 하링토니아 바 드루파시아 (Cephalotaxus harringtoniavar.drupacea)에서 분리된 호모하링토닌 (homoharringtonin), 푸사리움 솔라니(Fusarium solani)에서 분리된 4-이포메아놀 (4-ipomeanole) 등이 있다 (Cordell et al., Bioactive Natural Products, CRS Press, 195-220 (1993); Cragg et al., Human Medicinal Agents from Plants, American Chemical Society, 534-553 (1993)).There are about 150,000 plants on earth. The two plants are an important resource in the development of cancer is, and its examples are separated from Cantabria Lantus Rosedale mouse (Catharanthus roseus) is the empty bra Destin (vinblastine), grape pilrum Pell tatum (Podophyllum peltatum) with the alkaloids (alkaloid) separated from the lignans ( Taxol, Camptotheca accuminata , isolated from etonan, teniposide, and taxus brevifolia , a semisynthetic derivative of lignan podophyllotoxin ) separated from the camptothecin (camptothecine), three arms TAXUS haring Estonian bar drupa Asia (Cephalotaxus harringtonia var. drupacea) the Queer haring tonin (homoharringtonin), Fusarium solani (Fusarium solani) separated from the separation from 4- Ipomeanol (4-ipomeanole) and the like (Cordell et al., Bioactive Natural Products, CRS Press, 195-220 (1993); Cragg et al., Human Medicinal Agents from Plants, American Chemical Society, 534-553 (1993)).
이에 본 발명자들은 한방에서 많이 사용되는 생약제 기원의 항암제를 연구한 결과, 생약 성분에서 분리된 안토파인이 우수한 항암활성을 나타내는 것을 확인하고 본 발명을 완성하기에 이르렀다.Accordingly, the present inventors have studied the anticancer agent of the herbal medicine origin that is widely used in herbal medicine, and as a result, antopine isolated from the herbal components confirmed excellent anticancer activity and came to complete the present invention.
본 발명은 유효량의 안토파인을 포함하는 항암용 약학 조성물 및 상기 약학 조성물을 환자에게 투여하여 암을 예방 내지 치료하는 방법을 제공한다.The present invention provides an anticancer pharmaceutical composition comprising an effective amount of antepine and a method for preventing or treating cancer by administering the pharmaceutical composition to a patient.
본 발명은 박주가리과 식물로부터 안토파인을 분리하는 방법을 제공한다.The present invention provides a method for separating anthine from gourds.
본 발명은 암세포의 세포사멸을 측정하거나 및 암세포의 성장 저해능을 측정하는 것을 특징으로 하는 안토파인이 고농도 함유된 분획을 스크리닝하는 방법을 제공한다.The present invention provides a method for screening a fraction containing high concentrations of anthopines, characterized by measuring apoptosis of cancer cells or measuring growth inhibition of cancer cells.
도 1은 안토파인의 사람 폐암세포독성 효과를 나타낸 그래프이다.1 is a graph showing the effect of antagonist human lung cancer cytotoxicity.
도 2는 안토파인의 사람 결장암세포독성 효과를 나타낸 그래프이다.Figure 2 is a graph showing the cytotoxic effect of anthofine in human colon cancer.
도 3은 안토파인의 사람 결장암세포 성장억제 효과를 나타낸 현미경사진이다.Figure 3 is a micrograph showing the growth inhibitory effect of antagonist human colon cancer cells.
도 4는 안토파인의 사람결장암세포에 대한 세포성장주기에 미치는 영향을 나타낸 플로우 사이토미터 분석 그래프이다.Figure 4 is a flow cytometer analysis graph showing the effect of antagonist on the cell growth cycle of human colon cancer cells.
본 발명은 암의 예방 및 치료에 관한 것이다. 구체적으로는 본 발명은 유효량의 안토파인을 포함하는 항암용 약학 조성물 및 상기 약학 조성물을 환자에게 투여하여 암을 예방 내지 치료하는 방법을 제공한다. 안토파인은 하기 화학식 (I)로 표시되는 천연 물질이다.The present invention relates to the prevention and treatment of cancer. Specifically, the present invention provides an anticancer pharmaceutical composition comprising an effective amount of antepine and a method for preventing or treating cancer by administering the pharmaceutical composition to a patient. Antepine is a natural substance represented by the following general formula (I).
[화학식 (Ⅰ)][Formula (I)]
안토파인은 박주가리과 (Asclepiadaceae) 식물의 소수종에서 발견되는 알칼로이드이다. 본 발명에서는 안토파인을 천연물 생약으로 이용되고 있는 산해박의 추출물에서 분리하였다. 산해박(Cynanchum paniculatumKitagawa)은 박주가리과(Asclepiadaceae) 백미꽃속 다년생 초본식물로 주로 우리나라 전국의 산야에서 자라며 일본, 만주, 중국 등에 분포한다 (배기환 한국의 약용식물, 교학사, 412-414 (1999)). 박주가리과 백미꽃 속은 전세계 100종이 있으며 우리나라에 약 10여종이 분포하고 있는데, 원래 백미꽃의 뿌리 생약이 백미이지만 우리나라에서는 약재로 쓰이는 백미꽃(Cynanchum atratumBunge), 민백미꽃(Cynanchum ascyrifoliumMatsmura)과 산해박(Cynanchum paniculatumKitagawa)의 뿌리를 모두 백미(白薇)라 하여 혼용하고 있으며, 산해박의 뿌리가 백미로 시판되고 있다 (김윤식등 원색 한국 식물 도감, 아카데미 서적, 446-449 (1985)).Antepine is an alkaloid found in a few species of the Asclepiadaceae plant. In the present invention, the antepine was isolated from the extract of acid seabacterium which is used as a natural product herbal. Cynanchum paniculatum Kitagawa is a perennial herbaceous genus of Asclepiadaceae, which grows in the mountains of Korea and is distributed in Japan, Manchuria, and China. There are deceived bakjugarigwa baekmikkot 100 species worldwide and about 10 species distributed in the country, but the roots of herbal original baekmikkot rice country in baekmikkot (Cynanchum atratum Bunge) is used as a medicine, civil baekmikkot (Cynanchum ascyrifolium Matsmura) and sanhae night (Cynanchum paniculatum The roots of Kitagawa are all mixed with white rice, and the roots of Sanhaebak are marketed as white rice (Kim Yoon-sik and others, Book of Korean plants, Academy books, 446-449 (1985)).
산해박의 뿌리 생약은 이를 백미(白薇)라 하는 반면 그 전초 생약은 서장경(徐長卿)이라 한다 (임록재 등 조선약용식물지, 한국문화사 (1999)). 뿌리 생약에 대한 고전의 기록은 별로 없으나 전초 생약인 서장경은 고전에서 충독(蟲毒), 전염병, 사악기(邪惡氣), 온학(溫虐) 또는 정신이 혼미한 증세를 치료하고, 원기를 북돋우고 풍사를 몰아내며 허리와 무릎을 튼튼하게 하고 뱀독을 풀어주며 나아가 풍습 골통, 심위기통, 타박상으로 붓고 아픈 증상, 대상 포진, 간경변에 의한 복수, 월경 불순, 월경통을 치료한다고 기록되어 있다 (김창민등 완독 중약대사전, 정담, (1999)). 서장경은 이명(異名)으로 죽엽세신(竹葉細辛), 별선종(別仙踪), 천죽(天竹), 계류(溪柳), 사초(蛇草) 또는 료작죽(療勺竹)이라고도 한다.The root herb of Sanhaebak is called white rice, while the outpost herb is called Seo Jang-kyung (Lim, Rok-jae and other medicinal plants, Korean Cultural History (1999)). Although there are few records of classics about root herbal medicines, Seo Jang-kyung, an outpost herb, cures, refreshes, and arouses the symptoms of classic detoxification, epidemics, quartet, warmth, or confusion. It is said to cure stiffness in the lower back and knees, to release snake venom, and to cure swelling symptoms, shingles, cirrhosis, ascites, dysmenorrhea, dysmenorrhea, and dysmenorrhea. Chinese Medicine Dictionary, Jungdam, (1999)). Seo Jang-kyung is also known as bamboo leaf seed, bamboo, seonju, cheon bamboo, mountain stream, sedge or ryoza bamboo. .
최근에 산해박의 전초에는 주성분으로 1% 이상의 파에오놀 (paeonol)이 함유되어 있어 진통작용과 진정작용을 나타낸다는 문헌 보고가 있었고 (You, Chinese Medica, Harwood Academic Publishers, 270-278 (1998); Lee et al, 생약학회지,11, 66-68 (1980)), 그 뿌리 및 근경에는 사포닌(saponin), 스테로이드 (steroid), 디트피노이드 (diterpenoid) 등이 포함되어 있다고 알려져 있으며 (Sugama et al., Chem. Pharm. Bull.,34, 4500-4507 (1986); Qui et al., Abst. Chi. Med.,1, 113-129 (1986)), 산해박은 또한 종양괴사인자 (tumor necrosis factor)의 억제 효능 (Cho 등, Nat. Prod. Sci.,5, 12-19 (1999)), 혈중 콜레스테롤 저하 효능 및 항박테리아 효능 (antibacterial activity)을 나타낸다고도 알려져 있다 (You, Chinese Medica, Harwood Academic Publishers (1998)). 그러나, 산해박으로부터 암세포독성 및 암세포 성장저해 효능 물질이 분리된 바는 아직 없었다.Recently, there have been literature reports of over 1% paeonol as an active ingredient in wild seaweed outposts, showing analgesic and sedation (You, Chinese Medica, Harwood Academic Publishers, 270-278 (1998); Lee et al., Journal of Pharmacognosy, 11 , 66-68 (1980)), roots and rhizomes are known to contain saponins, steroids, diterpenoids (Sugama et al. , Chem. Pharm. Bull., 34 , 4500-4507 (1986); Qui et al., Abst. Chi.Med., 1 , 113-129 (1986)), and acidic peppers are also tumor necrosis factors. (Cho et al., Nat. Prod. Sci., 5 , 12-19 (1999)), blood cholesterol lowering effect and antibacterial activity (You, Chinese Medica, Harwood Academic Publishers) (1998). However, no cancer cytotoxicity and cancer cell growth inhibitory substances have been isolated from acid seabacterium.
본 발명자들은 산해박에서 분리된 상기 화학식 I의 안토파인이 암세포독성 효과 및 암세포성장저해 효능 활성이 있음을 실험으로 증명하였다. 안토파인은 시험관내 (in vitro) 실험에서 사람 폐암세포에 대한 독성 평가 결과 IC50가 3.2 pg/ml로서 높은 암세포 독성 활성을 나타내었으며 (도 1), 또한 사람 결장암세포에 대한 독성 평가 결과에서도 IC50가 4.3 pg/ml로서 높은 암세포 독성 활성을 나타내었다 (도 2). 이는 기존의 항암제, 예를 들면 택솔 (IC50= 0.007 μg/ml, 사람 폐암세포; IC50=0.003 μg/ml, 사람 결장암세포) 및 엘립티신 (IC50= 0.5 μg/ml, 사람 폐암세포; IC50=0.3 μg/ml, 사람 결장암세포) 보다도 높은 암세포 독성을 나타내는 값이다.The present inventors have experimentally demonstrated that the anthopine of the formula (I) isolated from Sanhaebak has cancer cytotoxic effect and cancer cell growth inhibitory activity. Antepine showed high cancer cell toxicity activity as IC 50 was 3.2 pg / ml as a result of toxicity evaluation on human lung cancer cells in vitro (Fig. 1), and also in the toxicity evaluation result on human colon cancer cells. 50 was 4.3 pg / ml, indicating high cancer cytotoxic activity (FIG. 2). This includes existing anticancer agents such as taxol (IC 50 = 0.007 μg / ml, human lung cancer cells; IC 50 = 0.003 μg / ml, human colon cancer cells) and ellipsine (IC 50 = 0.5 μg / ml, human lung cancer cells; IC 50 = 0.3 μg / ml, human colon cancer cells).
한편, 사람 결장암세포를 이용하여 세포독성에 관한 작용 기전을 살펴본 바, 안토파인은 직접 암세포를 죽이는 것이라기 보다는 암세포의 성장을 정지시키는 것으로 나타났으며 (도 3), 암세포 성장 주기 중에서 G2/M phase를 정지시킴으로서 (arrest) 암세포 성장을 억제하는 것으로 밝혀졌다(도 4).On the other hand, using human colon cancer cells to examine the mechanism of action on cytotoxicity, it was found that anthofine stops the growth of cancer cells rather than killing cancer cells directly (Fig. 3), G2 / M in the cancer cell growth cycle It has been shown to inhibit cancer cell growth by stopping the phase (arrest) (FIG. 4).
따라서, 본 발명은 암을 치료하기에 충분한 양의 안토파인을 유효 성분으로 하는 항암 조성물 및 상기 항암 조성물을 투여하여 암세포 암을 치료하는 방법을 제공한다. 본 발명의 조성물은 약학적으로 허용 가능한 담체를 포함할 수 있다. 담체는 제약 분야에서 통상 사용되는 용매, 분산 매질, 흡수 지연제 등을 포함한다. 본 발명의 약학 조성물은 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를통하여 투여될 수 있다. 따라서, 본 발명의 조성물은 국부, 경구, 비경구, 비내, 정맥내, 근육내, 피하, 안내, 경피등으로 투여될 수 있고, 용액, 현탁액, 정제, 환약, 캡술, 서방형 제제 등으로 제형할 수 있다. 바람직한 제형은 주사제이다. 투여량은 환자의 질병 종류 및 정도, 연령, 성별 등에 따라 당업계의 기술을 고려하여 결정한다.Accordingly, the present invention provides an anticancer composition comprising an antepine in an amount sufficient to treat cancer, and a method for treating cancer cell cancer by administering the anticancer composition. The composition of the present invention may comprise a pharmaceutically acceptable carrier. Carriers include solvents, dispersion media, absorption retardants, and the like commonly used in the pharmaceutical art. The pharmaceutical composition of the present invention may be administered via any general route as long as it can reach the desired tissue. Thus, the compositions of the present invention may be administered topically, orally, parenterally, intranasally, intravenously, intramuscularly, subcutaneously, intraocularly, transdermally, and formulated into solutions, suspensions, tablets, pills, capsules, sustained release formulations, and the like. can do. Preferred formulations are injections. Dosage is determined in consideration of the skill of the art depending on the type and extent of the disease, age, sex, etc. of the patient.
나아가, 본 발명은 유효량의 안토파인을 포함하는 암예방 내지 암 치료용 조성물 및 이를 투여하여 암을 치료하는 방법을 제공한다. 본 발명의 약학 조성물은 약학적으로 허용 가능한 담체를 포함할 수 있다. 담체는 제약 분야에서 통상 사용되는 용매, 분산 매질, 흡수 지연제 등을 포함한다. 본 발명의 약학 조성물은 국부, 경구, 비경구, 비내, 정맥내, 근육내, 피하, 안내, 경피등으로 투여될 수 있고, 용액, 현탁액, 정제, 환약, 캡술, 서방형 제제 등으로 제형할 수 있다. 바람직한 제형은 주사제이다. 투여량은 환자의 질병 종류 및 정도, 연령, 성별 등에 따라 당업계의 기술을 고려하여 결정한다. 본 발명의 약학 조성물은 뇌암, 난소암, 흉부암, 전립선암, 폐암, 간암, 결장암, 흑색종, 자궁 경부암, 자궁암, 위암, 신장암, 방광암, 표피양암 및 림프종 등의 질병을 치료하는 데 사용될 수 있다.Furthermore, the present invention provides a cancer prevention to cancer treatment composition comprising an effective amount of an antepine and a method for treating cancer by administering the same. The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier. Carriers include solvents, dispersion media, absorption retardants, and the like commonly used in the pharmaceutical art. The pharmaceutical compositions of the present invention may be administered topically, orally, parenterally, intranasally, intravenously, intramuscularly, subcutaneously, intraocularly, transdermally, and formulated into solutions, suspensions, tablets, pills, capsules, sustained release formulations, and the like. Can be. Preferred formulations are injections. Dosage is determined in consideration of the skill of the art depending on the type and extent of the disease, age, sex, etc. of the patient. The pharmaceutical composition of the present invention can be used to treat diseases such as brain cancer, ovarian cancer, chest cancer, prostate cancer, lung cancer, liver cancer, colon cancer, melanoma, cervical cancer, uterine cancer, gastric cancer, kidney cancer, bladder cancer, epidermal cancer and lymphoma Can be.
본 발명은 식물, 바람직하게는 박주가리과 식물, 더욱 바람직하게는 국내 자생식물인 산해박 (Cynanchum paniculatumKitagawa)으로부터 안토파인을 분리하는 방법을 제공한다. 안토파인은 이를 포함하는 식물에서 추출방법에 의하여 분리될 수 있다. 본 발명의 안토파인 분리 방법은 건조 식물 시료, 예를 들어 박주가리과 식물을 a) 물 또는 알코올로 추출하는 단계; b) 상기 추출물을 실리카 겔 컬럼 크로마토그라피 하는 단계; 및 c) 상기 실리카 겔 컬럼 크로마토그라피 용출액을 TLC하는 단계로 이루어지는 것을 특징으로 한다. 본 발명의 안토파인 분리 방법은 a) 단계 후, b) 단계 전에 메틸렌클로라이드 (methylene chloride)로 추출하는 단계를 임의로 포함할 수 있다.The present invention provides a method for separating anthopines from plants, preferably gourds, and more preferably from domestic seaweed ( Cynanchum paniculatum Kitagawa). Antepine may be separated from the plant containing the same by an extraction method. The method for separating an antepine of the present invention comprises the steps of: a) extracting a dry plant sample, for example acacia, with water or alcohol; b) silica gel column chromatography of the extract; And c) TLC the silica gel column chromatography eluate. The anthopine separation method of the present invention may optionally include extracting with methylene chloride after step a) and before step b).
본 발명자들은 산해박으로부터 상기 항암 효과에 기한 생물활성검정법을 사용하여 본 발명의 안토파인을 분리하였다 (실시예 1 및 실시예 2). 분리된 화합물은 각종 이화학적 성상, 기기분석 자료를 통하여 그 구조가 페난트로인돌리지딘 (phenanthroindolizidine) 알칼로이드 골격을 지닌 안토파인으로 밝혀졌다. 안토파인 유도체는 최근 같은 속 식물인 시난츔 빈베톡시쿰(Cynanchum vinvetoxicum)에서 분리 보고된바 있으나 (Staek 등, J. Nat. Prod.,63, 1584-1586 (2000)), 본 발명 이전에 산해박으로부터 분리 보고된 적은 없었다.The present inventors have separated the anthopines of the present invention from the acidic bacterium using the bioactivity assay based on the anticancer effect (Examples 1 and 2). The isolated compounds were identified as anthopines with phenanthroindolizidine alkaloid backbone through various physicochemical properties and instrumental analysis data. Antofine derivatives have recently been reported to be isolated from the same genus plant, Cynanchum vinvetoxicum (Staek et al., J. Nat. Prod., 63 , 1584-1586 (2000)). There have been no reports of separation from gourds.
본 발명의 안토파인은 암세포의 성장을 억제할 수 있음이 입증되었는 바 본 발명은 안토파인을 함유하는 암예방용 또는 암세포 성장 억제용 식품 조성물을 제공한다. 기재로 되는 식품은 특히 한정되는 것은 아니고, 물, 청량 음료나 과실 음료등의 드링크류, 과자류, 빵류, 면류, 조미료등, 여러가지의 식품을 기재로 할 수가 있다. 본 발명의 식품은 기재로 되는 식품의 제조공정에 상술한 본 발명의 조성물을 첨가하는 공정을 가함으로써 혹은 기재로되는 식품의 제조 후에 상술한 본 발명의 조성물을 첨가하는 공정을 가함으로써, 용이하게 얻을 수가 있다. 이때, 필요에 따라 맛과 냄새 교정제를 첨가하여도 좋다. 본 발명의 식품에 있어서의 상술한 조성물의 함유량은 목적으로 하는 식품의 종류나 기호 등에 따라 다르나, 안토파인이 원래 지닌 암예방 효과 및 보건 치료 효과를 충분히 활용하는데 있어 안토파인을 함유하는 식물 추출물을 0.1중량% 이상으로 하는 것이 바람직하다. 이와 같이 하여 얻어지는 본 발명의 식품은, 안토파인이 원래 지닌 보건 예방 효과 및 보건 치료 효과를 충분히 활용할 수 있는 식품이다.It has been proved that the anthopine of the present invention can inhibit the growth of cancer cells. The present invention provides a food composition for cancer prevention or cancer cell growth containing anthopine. The food used as a base material is not specifically limited, Various foods, such as drinks, confectionery, bread, noodles, seasonings, such as water, a soft drink, or a fruit drink, can be based on. The food of this invention is easily made by adding the process of adding the composition of this invention mentioned above to the manufacturing process of the base food, or by adding the process of adding the composition of this invention mentioned above after manufacture of the food of base materials. You can get At this time, you may add a taste and odor correction agent as needed. The content of the above-mentioned composition in the food of the present invention varies depending on the type and preference of the food of interest, but the plant extract containing anthpine is sufficiently utilized to fully utilize the cancer prevention effect and health treatment effect that antine originally had. It is preferable to set it as 0.1 weight% or more. The food of this invention obtained in this way is a food which can fully utilize the health prevention effect and health treatment effect which antepine originally had.
본 발명은 사람암세포에 대한 세포독성 및 /또는 사람 암세포 성장 저해능을 측정함으로서 안토파인이 고농도로 함유된 분획을 스크리닝하는 방법을 제공한다. 본 발명이 제공하는 안토파인의 생물활성검정법은 안토파인이 고농도로 농축된 분획을 찾는데 유용하게 사용될 수 있다. 본 발명의 생물활성검정법은 바람직하게는 문헌에 기재된 바와 같은 술포호다민 B (sulforhodamine B: SRB) 측정법 (Lee et al, Chemico-Biol. Interact.,115, 215-228 (1998)) 또는 플로우 사이토미터 분석 (flow cytometer analysis) 방법이다.The present invention provides a method for screening fractions containing high concentrations of anthopines by measuring cytotoxicity against human cancer cells and / or human cancer cell growth inhibition. The bioactivity assay of an antepine provided by the present invention can be usefully used to find a fraction in which an antepine is concentrated at a high concentration. The bioactivity assay of the present invention is preferably a sulfohodamine B (SRB) assay (Lee et al, Chemico-Biol. Interact., 115 , 215-228 (1998)) or flow cytos as described in the literature. Flow cytometer analysis.
다음의 실시예들은 본 발명을 예시하기 위한 것이다. 따라서, 본 발명의 범위가 하기 실시예에 의하여 제한되어서는 안된다.The following examples are intended to illustrate the invention. Therefore, the scope of the present invention should not be limited by the following examples.
<실시예 1><Example 1>
안토파인의 분리 및 정제Isolation and Purification of Antofine
건조된 산해박 3㎏을 100% 메탄올로 환류냉각 장치를 이용, 수욕상에서 3시간씩 3회 추출하였다. 추출물을 여과한 다음 감압 농축하여 370g의 산해박 메탄올 추출물을 얻었다. 메탄올 추출물을 증류수에 분산하고 헥산(hexane), 메틸렌클로라이드 (methylene chloride), 에틸아세테이트 (ethyl acetate), n-부탄올 (n-buthanol) 순으로 추출하여 각 용매의 가용 분획과 수층을 얻고 각 분획에 대하여실시예 3의 방법에 따라 활성실험을 하였다.3 kg of dried acidic seaweed was extracted with 100% methanol three times for 3 hours in a water bath. The extract was filtered and concentrated under reduced pressure to give 370 g of acidic methanol extract. By dispersing the methanol extract in distilled water and extracted with hexane (hexane), methylene chloride (methylene chloride), ethyl acetate (ethyl acetate), n- butanol (n -buthanol) in order to obtain a soluble fraction and aqueous layer of each solvent in each fraction The activity experiment was carried out according to the method of Example 3.
용매 분획중 가장 활성이 높은 메틸렌클로라이드 분획 (73 g)에 대해 클로로포름/아세톤 (50:1 - 1:1) 구배로 실리카겔 칼럼 크로마토그래피를 실시하여 10개의 분획으로 나누었다. 활성이 가장 높은 9번 분획 (IC50=1.0 μg/ml, 사람폐암세포; IC50=1.3 μg/ml, 사람결장암세포)을 취하여 다시 클로로포름/메탄올 (20:1 - 1:1)의 구배로 실리카겔 칼럼 크로마토그래피를 실시하여 5개의 분획을 얻었다. 가장 활성이 높은 2번째 분획 (IC50= 0.007 μg/ml, 사람폐암세포; IC50=0.004 μg/ml, 사람결장암세포)에 대하여 프랩티엘시 (preparative TLC; methylene chloride: methanol = 8:1, Rf=0.55) 및 프랩 HPLC (preparative HPLC, methanol:water = 97:3)를 하여 순수 유효 성분 Ⅰ (5 mg)을 분리하였다. 분리된 화합물은 미황색의 분말이었으며, 메틸렌클로라이드, 메탄올 용매에는 잘 녹으나 물, 아세톤 등에는 잘 녹지 않는다.The most active methylene chloride fraction (73 g) in the solvent fraction was subjected to silica gel column chromatography with a chloroform / acetone (50: 1-1: 1) gradient and divided into 10 fractions. Take 9 fractions with the highest activity (IC 50 = 1.0 μg / ml, human lung cancer cells; IC 50 = 1.3 μg / ml, human colon cancer cells) and take a gradient of chloroform / methanol (20: 1-1: 1) Silicagel column chromatography was performed to obtain five fractions. Preparative TLC; methylene chloride: methanol = 8: 1, for the second most active fraction (IC 50 = 0.007 μg / ml, human lung cancer cells; IC 50 = 0.004 μg / ml, human colon cancer cells) Pure active ingredient I (5 mg) was isolated by Rf = 0.55) and prep HPLC (preparative HPLC, methanol: water = 97: 3). The separated compound was a pale yellow powder, which was well soluble in methylene chloride and methanol solvent but insoluble in water and acetone.
실시예 2Example 2
화합물의 구조 결정Determine the structure of the compound
분석 HPLC (analytical HPLC)를 이용하여 실시예 1에서 분리한 성분의 순도를 평가하였다. 단일 성분임이 확인된 상태에서 각종 분광학적 실험 즉, H1-NMR, C13-NMR, DEPT, H1-H1COSY, H1-C13COSY, HMBC, positive FABMS를 실시하고 그 결과를 종합하여 구조를 결정하였다. 구조를 결정하기 위하여 먼저1H,13C의 일차원 스펙트라 (1D spectra)를 얻고 DEPT(Distortioless Enhancement Polarization Transfer) 실험으로 탄소의 복합성 (multiplicity)를 조사하였다. 분리된 화합물의 복합성을 표 1에 나타내었다.13C-NMR에서 55.5, 55.9, 56.0 ppm의 메톡시기 (methoxy group)의 위치를 뚜렷하게 알 수 있었다. 또한 탄소의 화학전이 (chemical shift)를 보면 120 ∼ 160 ppm사이의 방향족 고리 (aromatic ring)가 보이며 방향족 고리에 있는 CH-기가 103 ∼ 115 ppm에 걸쳐서 나타난다. 지방족 고리 (aliphatic cyclic ring)에 있는 CH2-기에 해당하는 피크가 상위 필드(upfield)에서 나타남을 알 수 있고 이들이 인접한 질소(N)에 의하여 하위 필드 (down field)로 전이(shift)된 피크도 존재함을 알 수 있다. HMQC(Heteronuclear Multiple Quantum Correlation)와 HMBC (Heteronuclear Multiple Bond Correlation) 2차원(2D) 실험들도 2k x 256 (t2 x t1) 데이터 값으로 얻었다.Analytical HPLC was used to evaluate the purity of the components isolated in Example 1. Various spectroscopic experiments are performed in the state identified as a single component, that is, H 1 -NMR, C 13 -NMR, DEPT, H 1 -H 1 COZY, H 1 -C 13 COZY, HMBC, and positive FABMS. The structure was determined. In order to determine the structure, 1D spectra of 1 H and 13 C were first obtained, and carbon multiplicity was examined by DEPT (Distortless Enhancement Polarization Transfer) experiment. Complexity of the isolated compounds is shown in Table 1. The position of methoxy groups of 55.5, 55.9 and 56.0 ppm was clearly identified in 13 C-NMR. In addition, the chemical shift of carbon shows an aromatic ring between 120 and 160 ppm, and the CH-group in the aromatic ring is present over 103 to 115 ppm. It can be seen that the peak corresponding to the CH 2 -group in the aliphatic cyclic ring appears in the upfield, and also the peak shifted to the downfield by adjacent nitrogen (N). It can be seen that it exists. Heteronuclear multiple quantum correlation (HMQC) and heteronuclear multiple bond correlation (HMBC) two-dimensional (2D) experiments were also obtained with 2k x 256 (t2 x t1) data values.
1D 1H-NMR 스펙트라부터 얻어진 값이 바움가르트너(Baumgartner) 등이 보고한 구조 (Phytochemistry,29, 3327-3330 (1990))와 일치하며, 안토파인 (antofine)과 거의 동일한 것으로 나타났다. 모든 H 수와 J 값이 일치하며 이들의 복합성 (multiplicity)도 일치한다. 또한 포지티브 FAB 매스-스펙트로스코피 (positive FAB mass-spectroscopy)를 측정한 결과 M+1이 364.3로써 분자량은 363으로 추정되었다. 위 물질이 알칼로이드임을 확인하기 위하여 알칼로이드 반응시험을 실시한 결과 플라티닉 클로라이드 (platinic chloride)를 분무하였을 때 연분홍색의 양성 반응을 보였다. 따라서 위 결과들을 종합하여 본 발명자들은 산해박에서분리된 단일 물질이 알칼로이드의 일종인 안토파인(antofine)임을 확인하였다.The value obtained from the 1D 1H-NMR spectra was consistent with the structure reported by Baumgartner et al. (Phytochemistry, 29 , 3327-3330 (1990)), and appeared to be nearly identical to antofine. All H numbers and J values match, and their multiplicity also matches. Also, the positive FAB mass-spectroscopy measured M + 1 as 364.3 and molecular weight as 363. The alkaloid reaction test was performed to confirm that the above material was an alkaloid, and when it was sprayed with platinum chloride, it showed a light pink positive reaction. Therefore, by combining the above results, the present inventors confirmed that the single substance separated from acid seaweed is anthopine (antofine), which is a kind of alkaloid.
표1. 화합물 I의 NMR spectral data (CDCl3, 600MHz)Table 1. NMR spectral data of compound I (CDCl 3 , 600 MHz)
실시예 3Example 3
시험관 내에서 사람암세포 독성 효능 측정Determination of Efficacy of Human Cancer Cell Toxicity in Vitro
안토파인이 세포 성장에 미치는 영향은 술포호다민 B (sulforhodamine B: SRB법)으로 측정하였다 (Lee et al, Chemico-Biol. Interact.,115, 215-228 (1998)). 사람암세포주 (A549, 사람폐암세포; Col2, 사람결장암세포)를 10% FBS, 1% PSF 등을 함유한 MEME 배지에서 계대 배양하였다. 96-웰 플레이트의 각 웰에 10% DMSO에 녹아있는 시료 10 ㎕와 상기 세포현탁액 190 ㎕ (5 x 104cells/ml)(MEME 배지)를 넣고 3일간 배양하였다. 적어도 16 웰에 상기 세포현탁액 190 ㎕를 넣고 30분간 배양하여 실험 전의 음성대조 (zero-day control)로 사용하였다. 배양한 세포를 10% TCA (trichloroacetic acid)로 고정시킨 후 SRB 용액으로 염색하고, 10 mM 트리스 베이스 (Tris-base)로 염색액을 용해시킨 다음 515 nm에서 흡광도를 측정하였다. 10% DMSO에서 배양한 경우를 대조군으로하여 각 시험 물질처리에 따른 세포 생존율을 아래의 식에 따라 환산하였다.The effect of anthopines on cell growth was measured by sulfohodamine B (SRB method) (Lee et al, Chemico-Biol. Interact., 115 , 215-228 (1998)). Human cancer cell lines (A549, human lung cancer cells; Col2, human colon cancer cells) were passaged in MEME medium containing 10% FBS, 1% PSF and the like. In each well of a 96-well plate, 10 μl of sample dissolved in 10% DMSO and 190 μl of the cell suspension (5 × 10 4 cells / ml) (MEME medium) were added and incubated for 3 days. 190 μl of the cell suspension was added to at least 16 wells and incubated for 30 minutes to be used as a zero-day control before the experiment. The cultured cells were fixed with 10% trichloroacetic acid (TCA) and stained with SRB solution, and the dye solution was dissolved with 10 mM Tris-base, and the absorbance was measured at 515 nm. In the case of incubation in 10% DMSO as a control, the cell viability according to each test substance treatment was converted according to the following equation.
시료를 처리하지 않은 대조군을 100%로 하였을 때 시료 처치군의 값을 대조군에 대한 백분율로 나타내었으며, 각 시험물질 처리는 이중 혹은 삼중 시험의 평균값 ± SEM으로 구하였다. IC50값은 50% 생존율에 대한 시험 물질의 농도이다. 안토파인이 사람암세포에 미치는 영향을 도1 및 도2에 나타내었다.When the control group was not treated with the sample at 100%, the value of the sample treatment group was expressed as a percentage of the control group, and each test substance treatment was calculated as the average value ± SEM of the double or triple test. IC 50 value is the concentration of test substance for 50% survival. 1 and 2 show the effects of anthopine on human cancer cells.
안토파인은 농도의존적으로 사람 암세포에 세포독성을 나타내었다. 사람 폐암세포에 대한 IC50는 3.2 pg/ml, 사람 결장암세포에 대한 IC50는4.3 pg/ml이었으며, 이는 양성대조군으로 사용한 항암제 택솔(taxol) (IC50=0.007 μg/ml, 사람폐암세포; IC50=0.003 μg/ml, 사람결장암세포) 및 엘립티신(ellipticine) (IC50= 0.5 μg/ml, 사람폐암세포; IC50=0.3 μg/ml, 사람 결장암세포)에 비하여 1000배 이상의 활성을 지닌 것이다.Antepine has been shown to be cytotoxic to human cancer cells in a concentration-dependent manner. The IC 50 for human lung cancer cells was 3.2 pg / ml, and the IC 50 for human colon cancer cells was 4.3 pg / ml, indicating that the antitumor taxol (IC 50 = 0.007 μg / ml, human lung cancer cells; IC 50 = 0.003 μg / ml, human colon cancer cells) and ellipticine (IC 50 = 0.5 μg / ml, human lung cancer cells; IC 50 = 0.3 μg / ml, human colon cancer cells) I have it.
실시예 4Example 4
시험관내에서 세포 형태 및 세포주기 관찰Observation of Cell Morphology and Cell Cycle in Vitro
사람 결장암세포인 Col2 세포를 10% FBS-MEME에 2 x 105cells/ml로 현탁하였다. 세포현탁액 10 ml를 10 cm 세포배양 디쉬에 부착시켰다. 시험물질(50 pg/ml 농도)을 첨가한 다음 37℃, 5% CO2에서 일정시간 배양하였다. 먼저 세포의 형태 변화를 관찰하기 위하여 세포를 24시간 배양한 다음 배양 배지를 걷어내고 PBS(phosphate buffered saline)로 2회 세척하였다. 형광현미경 하에서 100 배의 배율로 세포의 형태를 관찰하였다. 그 결과를 도 3에 나타내었다.Col2 cells, which are human colon cancer cells, were suspended in 10% FBS-MEME at 2 x 10 5 cells / ml. 10 ml of the cell suspension was attached to a 10 cm cell culture dish. Test substance (50 pg / ml concentration) was added and then incubated for a certain time at 37 ℃, 5% CO 2 . First, the cells were cultured for 24 hours to observe the morphological changes of the cells, and then the culture medium was removed and washed twice with PBS (phosphate buffered saline). The morphology of the cells was observed at 100 times magnification under fluorescence microscope. The results are shown in FIG.
시험물질들이 세포주기에 미치는 영향은 다음 방법으로 측정하였다. 시험물질(50 pg/ml 농도)을 세포에 처리하였다. 일정 시간 (24시간, 48시간, 72시간, 96시간)이 지난 후 트립신 처리를 하여 디쉬에 부착된 세포를 탈착시키고, 세포 배지 내에 부유되어 있는 세포와 상기 트립신 처리에 의하여 탈착된 세포를 원심분리하여 모은 다음, 이들 세포를 tris-saline 용액 (pH 7.0) 10 ml로 2회 세척한 다음 90% 에탄올 1.5 ml로 고정하였다. 포스페이트-시트레이트 (Phosphate-citrate) 버퍼 1 ml로 상온에서 2회 세척하고 PI (propidium iodide) 버퍼로 30분간 차광 염색한 후, PI 버퍼를 제거하고 PBS 1 ml로 현탁하였다. 세포 현탁용액을 5 ml 폴리스티렌 둥근바닥 튜브(polystyrene round bottom tube)로 옮겨서 플로우 사이토미터 분석 (flow cytometer analysis)을 시행하였다. 그 결과를 도 4에 나타내었다.The effect of the test substances on the cell cycle was measured by the following method. Test substance (50 pg / ml concentration) was treated with the cells. After a certain time (24 hours, 48 hours, 72 hours, 96 hours), trypsin treatment to detach the cells attached to the dish, centrifuged cells suspended in the cell medium and cells detached by the trypsin treatment The cells were washed twice with 10 ml of tris-saline solution (pH 7.0) and then fixed with 1.5 ml of 90% ethanol. After washing twice at room temperature with 1 ml of phosphate-citrate buffer and shading staining with propidium iodide (PI) buffer for 30 minutes, the PI buffer was removed and suspended in 1 ml of PBS. The cell suspension was transferred to a 5 ml polystyrene round bottom tube and subjected to flow cytometer analysis. The results are shown in FIG.
실험결과 안토파인은 결장암 세포에 대한 세포주기에서 G2/M phase에서 세포 성장을 멈추게하는 작용기전이 있음을 알 수 있다.As a result of the experiment, it can be seen that the anthopine has a mechanism of stopping cell growth in the G2 / M phase in the cell cycle for colon cancer cells.
본 발명의 안토파인은 사람 암세포에 대한 세포독성이 강하므로 암세포를 사멸시킬 수 있는 항암제 내지 암세포 성장 억제제로 사용될 수 있다. 본 발명은 또한 상기 안토파인을 천연 생약 물질인 산해박으로부터 분리하는 방법과 안토파인의 활성을 스크린하는 생물활성검정법을 제공한다.Antepine of the present invention can be used as an anticancer agent or a cancer cell growth inhibitor that can kill cancer cells because of its high cytotoxicity against human cancer cells. The present invention also provides a method for separating the antepine from an acidic herb, a natural herbal substance, and a bioactivity assay for screening the activity of the antepine.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010050497A KR20030016774A (en) | 2001-08-21 | 2001-08-21 | Compositions Comprising Antofine And The Use Thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010050497A KR20030016774A (en) | 2001-08-21 | 2001-08-21 | Compositions Comprising Antofine And The Use Thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030016774A true KR20030016774A (en) | 2003-03-03 |
Family
ID=27720182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020010050497A KR20030016774A (en) | 2001-08-21 | 2001-08-21 | Compositions Comprising Antofine And The Use Thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20030016774A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014512400A (en) * | 2011-04-29 | 2014-05-22 | インダストリアル テクノロジー リサーチ インスティテュート | Kinancum plant extract for the treatment of arthritis and active ingredients contained therein |
KR20150133515A (en) * | 2014-05-20 | 2015-11-30 | 대전대학교 산학협력단 | Anti-melanoma activity of Cynanchi atrati Radix extracts and manufacturing thereof |
WO2017222252A1 (en) * | 2016-06-21 | 2017-12-28 | 서울대학교산학협력단 | Pharmaceutical composition for preventing or treating colon cancer, containing extract of telectadium dongnaiense as active ingredient |
-
2001
- 2001-08-21 KR KR1020010050497A patent/KR20030016774A/en not_active Application Discontinuation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014512400A (en) * | 2011-04-29 | 2014-05-22 | インダストリアル テクノロジー リサーチ インスティテュート | Kinancum plant extract for the treatment of arthritis and active ingredients contained therein |
US9549958B2 (en) | 2011-04-29 | 2017-01-24 | Industrial Technology Research Institute | Extracts of Cynanchum sp. and active ingredients contained therein in use of arthritis treatment |
KR20150133515A (en) * | 2014-05-20 | 2015-11-30 | 대전대학교 산학협력단 | Anti-melanoma activity of Cynanchi atrati Radix extracts and manufacturing thereof |
WO2017222252A1 (en) * | 2016-06-21 | 2017-12-28 | 서울대학교산학협력단 | Pharmaceutical composition for preventing or treating colon cancer, containing extract of telectadium dongnaiense as active ingredient |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jahaniani et al. | Xanthomicrol is the main cytotoxic component of Dracocephalum kotschyii and a potential anti-cancer agent | |
Kumar et al. | Anticancer and immunostimulatory compounds from Andrographis paniculata | |
Torras Claveria et al. | Research in natural products: Amaryllidaceae ornamental plants as sources of bioactive compounds | |
KR20100026030A (en) | An extract of effective component for protection against other kinds of cancer, method for extracting the same and an anti-cancer medicine comprising it | |
KR100524373B1 (en) | A pharmaceutical composition containing the extract of saururus chinensis baill useful as an anticancer agent and a process for the preparation thereof | |
KR100750500B1 (en) | Novel Sargachromanol derivatives, a isolation method thereof, and a composition containing the same showing antioxidant activity | |
KR101131224B1 (en) | Coumarin compounds from Corydalis heterocarpa and Anticancer composition containing the same | |
Kerekes et al. | Coumarins, furocoumarins and limonoids of Citrus trifoliata and their effects on human colon adenocarcinoma cell lines | |
KR20010054264A (en) | Cordycepin separated from Cordyceps spp. for an anti-cancer medicine and its production | |
KR100623436B1 (en) | Pharmaceutical composition containing emodin for preventing and treating cancer from Rumex acetosa L | |
KR20030016774A (en) | Compositions Comprising Antofine And The Use Thereof | |
CN107286123B (en) | Preparation method and application of diphenyl furan compound | |
Feng et al. | Antitumor principles of Stellera chamaejasme L. | |
CN109320409A (en) | A kind of preparation method and applications with antimycotic and anti-tumor activity anthraquinone dimer class compound | |
Hasan et al. | Cytotoxic, antioxidant and antimicrobial activities of Ipomoea carnea spp. fistulosa (Mart. ex Choisy) D. Austin | |
WO2012144711A2 (en) | Composition containing caryopteris incana extracts or a compound isolated therefrom for preventing and treating hepatotoxicity | |
KR100447608B1 (en) | Method for Extraction, Isolation and Identification of trans-Resveratrol and Its Derivatives with Anticarcinogenic and Antimutagenic Activity from Paeonia lactiflora Seeds | |
KR100703597B1 (en) | Composition comprising phlorotannins or the extract of ecklonia stolonifera okamura having hepatoprotective effect on hep g2 cell cytotoxicity induced with tacrine | |
KR101021975B1 (en) | A composition for enhancing the radiotherapy of cancer | |
CN109180632A (en) | A kind of noval chemical compound isolated from tripterygium wilfordii and preparation method thereof and medical usage | |
KR100833654B1 (en) | Composition for preventing or treating osteoporosis comprising an extract of saururus chinensis or active compounds isolated therefrom | |
KR20150046482A (en) | Composition Comprising the Extract of Cirsium maackii for Preventing or Treating Liver Injury Induced Hepatotoxic Substances | |
KR20060028076A (en) | Composition containing yuanhuacine compound having an anti-cancer activity | |
US20070020346A1 (en) | Botanical anticancer formulations | |
CN115536532B (en) | Crotonane diterpenoid compound, preparation method, pharmaceutical composition and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Withdrawal due to no request for examination |